Forbion Capital Partners
Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
Business Model:
Revenue: $0
Employees: 2-10
Rankings
Industries / Tags:
Detailed Forbion Capital Partners Information
Geographic Data
Address: PO Box 5187
City: Naarden
State: flevoland
Zip: 1410
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Twitter
Linkedin
Crunchbase
Metrics
8,335,511Website Global Rank
447Website Monthly Traffic
Twitter Followers
Description
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion&s;s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 5/2015 | Replimune Group | Seed Round | 2M |
| 2/2022 | Complement Therapeutics | Seed Round | 5.7M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 1/2015 | enGene | Series B | 0 |
| 11/2018 | Inflazome | Series B | 45.8M |
| 11/2018 | OMEICOS Therapeutics | Series C | 0 |
| 9/2010 | Cardoz | Series A | 17.6M |
| 3/2018 | Escalier Biosciences | Series B | 19M |
| 3/2015 | Insmed | Post-IPO Equity | - |
| 1/2021 | Complement Therapeutics | Seed Round | - |
| 7/2017 | Exosome Diagnostics | Series C | 0 |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
| 1/2016 | Exosome Diagnostics | Series B | 0 |
| 11/2011 | CircuLite | Series D | 30M |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 11/2013 | Argos Therapeutics | Series E | 0 |
| 1/2021 | New Amsterdam Pharma | Series A | 0 |
| 6/2010 | Cytheris | Series D | 15M |
| 7/2005 | Xention | Series B | 13.3M |
| 10/2001 | Ardana Bioscience | Series A | 20M |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 4/2012 | Argos Therapeutics | Series D | 0 |
| 8/2007 | AM Pharma | Series C | 3.4M |
| 9/2011 | Amakem | Series A | 25.2M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 3/2005 | Borean Pharma | Series A | 0 |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 3/2010 | Promedior | Series C | 12M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 12/2013 | Ario Pharma | Seed Round | 3.1M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2013 | UniQure | Private Equity Round | 0 |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 4/2007 | CircuLite | Series B | 5M |
| 1/2010 | CircuLite | Series C | 32.5M |
| 9/2009 | arGEN-X | Series A | 13.6M |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 3/2014 | Exosome Diagnostics | Series B | 0 |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2011 | PneumRx | Venture Round | 0 |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 6/2015 | Realeve | Series D | 43.2M |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 6/2019 | SANIFIT | Series D | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 3/2008 | PanGenetics | Series C | 35.1M |
| 11/2021 | Prilenia | Series B | 0 |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 5/2012 | Mitralign | Series D | 0 |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 9/2017 | Replimune Group | Series B | 55M |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 9/2015 | SANIFIT | Series C | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 7/2021 | NeRRe Therapeutics | Series B | 0 |
| 9/2015 | Exosome Diagnostics | Series B | 0 |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 12/2002 | Transave | Series B | - |
| 11/2014 | Curetis | Series B | 0 |
| 2/2011 | CellNovo | Series B | 48.3M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 2/2013 | Dezima Pharma | Venture Round | 18.6M |
| 9/2015 | Replimune Group | Series A | 30M |
| 3/2021 | Oxular | Series B | 37M |
| 1/2021 | CoviCept Therapeutics | Seed Round | 2.3M |
| 9/2005 | Bioceros | Private Equity Round | - |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 6/2020 | Prilenia | Series A | 62.5M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 6/2021 | VectorY | Seed Round | 0 |
| 10/2004 | FlowMedica | Series C | 0 |
| 5/2010 | Exosome Diagnostics | Series A | 20M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 11/2006 | Pieris AG | Series B | 0 |
| 8/2009 | NovoGI | Series F | 0 |
| 1/2003 | Impella Cardiosystems | Venture Round | 40M |
| 12/2011 | arGEN-X | Series B | 43.8M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 11/2020 | Catalym | Series B | 59.3M |
| 8/2018 | KaNDy Therapeutics | Series C | 32.6M |
| 2/2016 | Akarna | Series B | 15M |
| 11/2011 | Oxyrane | Series D | 26.5M |
| 7/2011 | gIcare Pharma | Series A | 7.4M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 3/2012 | Promedior | Series D | 21.5M |
| 10/2012 | Promedior | Series D | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2021 | Gyroscope Therapeutics | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 4/2008 | Transave | Series D | 35M |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 3/2022 | Precirix | Series B | 0 |
| 3/2015 | Rigontec | Series A | 5.2M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 5/2023 | Dualyx | Series A | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 9/2016 | Rigontec | Series A | 16.9M |
| 10/2011 | Curetis | Series A | 13.3M |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 3/2009 | BioVex | Venture Round | 40M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 8/2016 | Catalym | Seed Round | - |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 11/2022 | CatalYm | Series C | 0 |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
